Ultravision Technologies, LLC v. Holophane Europe Limited, No. 2:19-cv-00291 (E.D. Tex. Oct. 25, 2020)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

On September 9, 2020, the Court held a hearing to determine the proper construction of the disputed claim terms within United States Patent Nos. 8,870,410 (“the ’410 Patent”); 8,870,413 (“the ’413 Patent”); 9,734,738 (“the ’738 Patent”); 9,947,248 (“the ’248 Patent”); and 10,223,946 (“the ’946 Patent”) (collectively, “the Asserted Patents”). Having reviewed the arguments made by the parties at the hearing and in their claim construction briefing, Dkt. Nos.